Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Baxter
Dow
Express Scripts
Boehringer Ingelheim

Last Updated: December 9, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,465,739

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,465,739
Title:Stable aqueous pharmaceutical formulations of daclizumab antibodies
Abstract: This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8.degree. C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.
Inventor(s): Kaisheva; Elizabet A. (Belmont, CA), Gupta; Supriya (Sunnyvale, CA), Duvur; Shanti G. (Fremont, CA), Subramanian; Malathy (Fremont, CA)
Assignee: Abbvie Biotherapeutics Inc. (Redwood City, CA)
Application Number:13/226,372
Patent Claims:1. A stable aqueous pharmaceutical formulation, comprising: about 20 mM to about 60 mM succinate buffer, about 0.01% to about 0.1% polysorbate, about 75 mM to about 150 mM sodium chloride, and at least about 100 mg/ml of a daclizumab antibody, wherein said aqueous pharmaceutical formulation has a pH in the range of about pH 5.5 to about pH 6.5; and wherein the daclizumab in said aqueous pharmaceutical formulation shows no more than 10% aggregation after 3 months at room temperature as measured by size exclusion chromatography.

2. The stable aqueous pharmaceutical formulation of claim 1 in which the polysorbate is polysorbate 80.

3. The stable aqueous pharmaceutical formulation of claim 1 in which the succinate buffer is sodium succinate.

4. The stable aqueous pharmaceutical formulation of claim 1 which has a pH of about pH 6.0.

5. The stable aqueous pharmaceutical of claim 1, in which the amount of polysorbate is about 0.01% to about 0.05%.

6. The stable aqueous pharmaceutical of claim 1, in which the amount of polysorbate is about 0.02% to about 0.04%.

7. The stable aqueous pharmaceutical formulation of claim 1, wherein the daclizumab in said aqueous pharmaceutical formulation shows no more than 5% aggregation after 3 months at room temperature as measured by size exclusion chromatography.

8. The stable aqueous pharmaceutical formulation of claim 1, wherein the daclizumab in said aqueous pharmaceutical formulation shows no more than 10% aggregation after 6 months at room temperature as measured by size exclusion chromatography.

9. The stable aqueous pharmaceutical formulation of claim 1, wherein the daclizumab in said aqueous pharmaceutical formulation shows no more than 5% aggregation after 6 months at room temperature as measured by size exclusion chromatography.

Details for Patent 8,465,739

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 1997-12-10 ⤷  Try it Free 2021-11-08
Biogen Inc. ZINBRYTA daclizumab Injection 761029 2016-05-27 ⤷  Try it Free 2021-11-08
Biogen Inc. ZINBRYTA daclizumab Injection 761029 2017-05-26 ⤷  Try it Free 2021-11-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Colorcon
Dow
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.